Reverse genetics and the study of dengue virus

Future Virology

Volumn 3, Issue 3, 2008, Pages 279-290

  Ward, Rebecca ^a   Davidson, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antiviral; Dengue vaccine; Dengue virus; Flavivirus; Replicon; Reverse genetics; Viral pathogenesis; Viral vaccine

Indexed keywords

ANTIVIRUS AGENT; COMPLEMENTARY DNA; DENGUE VACCINE; PYRAZOLINE DERIVATIVE; VIRUS PROTEIN; VIRUS RNA; VIRUS VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AEDES; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC MANIPULATION; HUMAN; INFECTION CONTROL; MEDICAL RESEARCH; MOLECULAR CLONING; PARASITE VECTOR; PATHOGENESIS; PRIORITY JOURNAL; REPLICON; REVIEW; VIRAL GENETICS; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ARTHROPODA; DENGUE VIRUS; FLAVIVIRUS;

EID: 44149124527     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.3.279     Document Type: Review

References (80)

1. Mackenzie JS, Gubler DJ, Petersen LR: Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-S109 (2004).
2. Gubler DJ: Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10, 100-103 (2002).
3. Fink J, Gu F, Vasudevan SG: Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev. Med. Virol. 16, 263-275 (2006).
4. Green S, Rothman A: Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19, 429-436 (2006).
5. Halstead SB: Dengue. Lancet 370, 1644-1652 (2007).
6. Lindenbach BD, Rice CM: Molecular biology of flaviviruses. Adv. Virus Res. 59, 23-61 (2003).
7. Lai CJ, Zhao BT, Hori H, Bray M: Infectious RNA transcribed from stably cloned full-length cDNA of dengue type virus. Proc. Natl. Acad. Sci. USA 88, 5139-5143 (1991).
8. Blaney JE Jr. Durbin AP, Murphy BR, Whitehead SS: Development of a live attenuated dengue virus vaccine using reverse genetics. Virol Immunol. 19, 10-3 (2006).
9. Bray M, Men R, Tokimatsu I, Lai CJ: Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J. Virol. 72, 1647-1651 (1998).
10. Kawano H, Rostapshov V, Rosen L, Lai CJ: Genetic determinants of dengue type 4 virus neurovirulence for mice. J. Virol. 67, 6567-6575 (1993).
11. Blaney JE Jr, Manipon GG, Firestone CY et al.: Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 21, 4317-4127 (2003).
12. Blaney JE Jr. Manipon GG, Murphy BR, Whitehead SS: Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice. Arch. Virol. 148, 999-1006 (2003).
13. Hanley KA, Lee JJ, Blaney JE Jr, Murphy BR, Whitehead SS. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J. Virol. 76, 525-531 (2002).
14. Gualano RC, Pryor MJ, Cauchi MR. Wright PJ, Davidson AD: Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol. 79(Pt 3), 437-446 (1998).
15. Kapoor M, Zhang L, Mohan PM, Padmanabhan R: Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain). Gene 162, 175-180 (1995).
16. Polo S, Ketner G, Levis R, Faigout B: Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast. J. Virol. 71, 5366-5374 (1997).
17. Kinney RM, Butrapet S, Chang GJ et al.: Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230, 300-308 (1997).
18. Sriburi R, Keelapang P, Duangchinda T et al.: Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid. J Virol. Methods 92, 71-82 (2001).
19. Blaney JE Jr. Hanson CT, Hanley KA, Murphy BR, Whitehead SS: Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4, 39 (2004).
20. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS: Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hyg. 71, 811-821 (2004).
21. Pierro DJ, Salazar MI, Beaty BJ, Olson KE: Infectious clone construction of dengue virus type 2, strain Jamaican 1409, and characterization of a conditional E6 mutation. J. Gen. Virol. 87, 2263-2268 (2006).
22. Suzuki R. de Borba L, Duarte dos Santos CN, Mason PW: Construction of an infectious cDNA clone for a Brazilian prototype strain of dengue virus type 1: characterization of a temperature-sensitive mutation in NS1. Virology 362, 374-383 (2007).
23. Guy B, Almond JW: Towards a dengue vaccine: progress to date and remaining challenges. Comp. Immunol. Microbiol. Infect. Dis. 31(2-3), 239-252 (2008).
24. Hombach J, Barrett AD, Cardosa MJ et al.: Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23, 2689-2695 (2005).
25. Kinney RM, Huang CY: Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44, 176-197 (2001).
26. Pugachev KV, Guirakhoo F, Trent DW, Monaaaath TP: Traditional and novel approaches to flavivirus vaccines. Int. J. Parasitol. 33, 567-582 (2003).
27. Whitehead SS, Blaney JE, Durbin AP, Murphy BR: Prospects for a dengue virus vaccine. Nat. Rev Microbiol. 5, 518-528 (2007).
28. Butrapet S. Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM: Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-63), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74, 3011-3019 (2000).
29. Cahour A, Pletnev A. Vazlelle-Falcoz M, Rosen L, Lai CJ: Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207, 68-76 (1995).
30. Men R, Bray M, Clark D, Chanock RM, Lai CJ: Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern hnd immunogenicity in rhesus monkeys. J Virol. 70, 3930-3937 (1996).
31. Durbin AP, Karron RA, Sun W et al.: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65, 405-413 (2001).
32. Durbin AP, Wh itehead SS, McArthur J et al.: rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly Infectious in healthy adult volunteers. J. Infect. Dis. 191, 710-718 (2005).
33. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR: A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol. 77, 1653-1657 (2003).
34. Durbin AP, McArthur J, Marron JA et al.: The live attenuated dengue serotype 1 vaccine rDEN1 Delta30 is safe and highly immunogenic in healthy adult Volunteers. Hum. Vaccin. 2, 167-173 (2006).
35. Blaney JE Jr. Sathe NS, Goddard L et al.: Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENU 3 3′-UTR with that of DENV-4. Vaccine 26, 817-828 (2008).
36. Zeng L, Falgout B, Markoff L: Identification of specific nucleotide sequences within the conserved. 3′-SL in the dengue type 2 virus genome required for replication. J. Virol. 72, 7510-7522 (1998).
37. Markoff L, Pang X, Houng HS et al.: Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol. 76, 3318-3328 (2002).
38. Bray M, Lai CJ: Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl Acad. Sci USA 88, 10342-10346 (1991).
39. Pletnev AG, Bray M, Huggins J, Lai CJ: Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl Acad. Sci. USA 89, 10532-10536 (1992).
40. Whitehead SS. Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR: Substitution of the structural genes of dengue virus type 4 With those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21, 4307-4316 (2003).
41. Durbin AR McArthur JH, Marron JA et al.: rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2, 255-260 (2006).
42. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM: Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77, 11436-11447 (2003).
43. Lai CJ, Monath TP: Chimeric flaviviruses: novel vaccines against dengue fever, tickborne encephalitis, and Japanese encephalitis. Adv Virus Res. 61, 469-509 (2003).
44. Guirakhoo F, Arroyo J, Pugachev KV et al.: Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 75, 7290-7304 (2001).
45. Monath TP: Dengue and yellow fever - challenges for the development and use of vaccines. N. Engl. J. Med. 357, 2222-2225 (2007).
46. Pugachev KV, Guirakhoo F, Monath TP: New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis. 18, 387-394 (2005).
47. Blaney JE Jr, Johnson DH, Firestone CY, Hanson CT, Murphy BR, Whitehead SS: Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in Vero cells or human liver cells and attenuated in mice. J. Virol. 75, 9731-9740 (2001).
48. Blaney JE Jr, Johnson DH, Manpon GG et al.: Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300, 125-139 (2002).
49. Hanley KA, Manlucu LR, Gilmore LE et al.: A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology, 312, 222-232 (2003).
50. Lee E. Wright PJ. Davidson A, Lobigs M: Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J. Gen. Virol. 87, 2791-2801 (2006).
51. Pryor MJ, Carr JM, Hocking H, Davidson AD, Li P, Wright PJ: Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 65, 427-434 (2001).
52. Cologna R, Rico-Hesse R: American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol. 77, 3929-3938 (2003).
53. Alvarez DE, Lodeiro MF, Luduena SJ, Pietrasanta LI, Gamarnik AV: Long-range RNA-RNA interactions circularize the dengue virus genome. J. Virol. 79, 6631-6643 (2005).
54. Sirigulpanit W, Kinney RM, Leardkamolkarn V: Substitution or deletion mutations between nt 54 and 70 In the 5′ non-coding region of dengue type 2 virus produce variable effects on virus viability. J. Gen. Virol. 88, 1748-1752 (2007).
55. Alvarez DE, De Lelia Ezcurra AL, Fucito S, Gamarnik AV: Role of RNA structures present at the 3′ UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339, 200-212 (2005).
56. Romero TA, Tumban E, Jun J, Lott WB, Hanley KA: Secondary structure of dengue virus type 4 3′ untranslated region: impact of deletion and substitution mutations. J Gen. Virol. 87, 3291-3296 (2006).
57. Tajima S, Nukul Y, Ito M, Takasaki T, Kurane I: Nineteen nucleotides in the variable region of 3′ non-translated region are dispensable for the replication of dengue type 1 virus in vitro. Virus Res. 116, 38-44 (2006).
58. Clyde K, Harris E: RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication. J. Virol. 80, 2170-2182 (2006).
59. Bryant JE, Calvert AE, Mesesan K et al.: Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes. Virology 366, 415-423 (2007).
60. Mondotte JA, Lozach PY, Amara A, Gamarnik AV: Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J Virol. 81, 7136-7148 (2007).
61. Crabtree MB, Kinney RM, Miller BR: Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch. Virol. 150, 771-786 (2005).
62. Pryor MJ, Gualano RC, Lin B, Davidson AD, Wright PJ: Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J. Gen. Virol. 79 (Pt 11), 2631-2639 (1998).
63. Matusan AE, Pryor MJ, Davidson AD. Wright PJ: Mutagenesis of the dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. J. Virol. 75, 9633-9643 (2001).
64. Kroschewski H, Lim SP. Butcher RE et al.: Mutagenesis of the dengue virus type 2 NS5 methyltransferase domain. J. Biol. Chem. (2008).
65. Matusan AE, Kelley PG, Pryor MJ, Whisstock JC, Davidson AD, Wright PJ: Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus. J. Gen. Virol. 82, 1647-1656 (2001).
66. Pryor MJ, Rawlinson SM. Butcher RE et al.: Nuclear localization of dengue virus nonstructural protein 5 through its importin α/ p-recognized nuclear localization sequences is integral to viral infection. Traffic 8, 795-807 (2007).
67. Malet H, Egloff MP, Selisko B et al.: Crystal structure of the RNA polymerase domain of the West Nile virus non-structural protein 5. J Biol. Chem. 282, 10678-10689 (2007).
68. Pang X, Zhang M, Dayton AI: Development of dengue virus type 2 replicons capable of prolonged expression in host cellt. BMC Microbiol. 1, 18 (2001).
69. Pang X, Zhang M, Dayton AI: Develoyment of dengue virus replicons expressing HIV-1 gp 120 and other heterologous genes: a polential future tool for dual vaccination against dengue virus and HIV. BMC Microbiol. 1, 28 (2001).
70. Holden KL, Stein DA, Pierson TC et al.: Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology, 344, 439-452 (2006).
71. Puig-Basagoiti F, Tilgner M, Forshey BM et al.: Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50, 1320-1329 (2006).
72. Jones M, Davidson A, Hibbert L et al.: Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol. 79, 5414-5420 (2005).
73. Ng CY, Gu F, Phong WY et al.: Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Anativiral Res. 76. 222-231 (2007).
74. Lai CY, Hu HP, King CC, Wang WK: Incorporation of dengue virus replicon into virus-like particles by a cell line stably expressing precursor membrane and envelope proteins of dengue virus type 2. J. Biomed. Sci. 15, 15-27 (2008).
75. Puri B, Polo S, Hayes CC, Falgout B: Construction of a full length infectious clone for dengue-1 virus Western Pacific, 74 strain. Virus Genes 20, 57-63 (2000).
76. Harvey TJ, Liu WJ, Wang XJ et al.: Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol. 78, 531-538 (2004).
77. Zhu W, Qin C, Chen S et al.: Attenuated dengue 2 viruses with deletions in capsid protein derived from an infectious full-length cDNA clone. Virus Res. 126, 226-232 (2007).
78. Filomatori CV, Lodeiro MF, Alvarez DE, Samsa MM, Pietrasanta L, Garnarnik AV: A 5′ RNA element promotes dengue virus RNA synthesis on a circular genome. Genes Dev. 20, 2238-2249 (2006).
79. Keelapang P, Sriburi R, Supasa S et al.: Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J. Virol. 78, 2367-2381 (2004).
80. Pryor MJ, Azzola L, Wright PJ, Davidson AD: Histidine 39 in the dengue virus type 2 M protein has an important role in virus ssembly. J. Gen. Virol. 85, 3627-3636 (2004).